The Full Wiki

More info on SKF-82,958

SKF-82,958: Wikis

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


(Redirected to SKF-82958 article)

From Wikipedia, the free encyclopedia

SKF 82958.png
IUPAC name
CAS number 80751-65-1
PubChem 1225
Molecular formula C19H20ClNO2
Molar mass 329.82 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

SKF-82958 (C-APB) is a synthetic compound that acts as a dopamine receptor D1 agonist.[1] The abbreviation SKF stands for Smith, Kline & French, a pharmaceutical company which later became GlaxoSmithKline. SKF-82958 and similar D1-selective full agonists like SKF-81297 and 6-Br-APB produce characteristic anorectic effects, hyperactivity and self-administration in animals, with a similar but not identical profile to that of dopaminergic stimulants such as amphetamine.[2][3][4][5][6][7][8][9][10]


  1. ^ Pfeiffer, Francis R.; Wilson, James W.; Weinstock, Joseph; Kuo, George Y.; Chambers, Pamela A.; Holden, Kenneth G.; Hahn, Richard A.; Wardell, Joseph R., Jr.; Alfonso, J. Tobia; et al. (1982). "Dopaminergic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines". Journal of Medicinal Chemistry 25 (4): 352–358.  
  2. ^ Terry P, Katz JL (1992). "Differential antagonism of the effects of dopamine D1-receptor agonists on feeding behavior in the rat". Psychopharmacology 109 (4): 403–9. PMID 1365854.  
  3. ^ Self DW, Stein L (June 1992). "The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats". Brain Research 582 (2): 349–52. PMID 1356585.  
  4. ^ Rosenzweig-Lipson S, Hesterberg P, Bergman J (September 1994). "Observational studies of dopamine D1 and D2 agonists in squirrel monkeys". Psychopharmacology 116 (1): 9–18. PMID 7862937.  
  5. ^ Kalivas PW, Duffy P (July 1995). "D1 receptors modulate glutamate transmission in the ventral tegmental area". The Journal of Neuroscience : the Official Journal of the Society for Neuroscience 15 (7 Pt 2): 5379–88. PMID 7623160.  
  6. ^ Weed MR, Woolverton WL (December 1995). "The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys". The Journal of Pharmacology and Experimental Therapeutics 275 (3): 1367–74. PMID 8531104.  
  7. ^ Weed MR, Paul IA, Dwoskin LP, Moore SE, Woolverton WL (October 1997). "The relationship between reinforcing effects and in vitro effects of D1 agonists in monkeys". The Journal of Pharmacology and Experimental Therapeutics 283 (1): 29–38. PMID 9336305.  
  8. ^ Abrahams BS, Rutherford JD, Mallet PE, Beninger RJ (February 1998). "Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434". European Journal of Pharmacology 343 (2-3): 111–8. PMID 9570457.  
  9. ^ Tidey JW, Bergman J (June 1998). "Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs". The Journal of Pharmacology and Experimental Therapeutics 285 (3): 1163–74. PMID 9618419.  
  10. ^ Berridge KC, Aldridge JW (September 2000). "Super-stereotypy I: enhancement of a complex movement sequence by systemic dopamine D1 agonists". Synapse (New York, N.Y.) 37 (3): 194–204. doi:10.1002/1098-2396(20000901)37:3<194::AID-SYN3>3.0.CO;2-A. PMID 10881041.  

Got something to say? Make a comment.
Your name
Your email address